Drug intelligence / Profile preview

propofol + ropivacaine

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Intravenous, Epidural

Overview

A combination of the general anesthetic propofol and the local anesthetic ropivacaine. Propofol is a sedative-hypnotic agent that acts through positive modulation of GABA-A receptors, while ropivacaine is a local anesthetic that blocks sodium channels to prevent nerve impulse generation and conduction. This combination is commonly used in surgical settings where both general anesthesia and regional pain control are desired, offering benefits such as reduced propofol requirements, better hemodynamic stability, and improved postoperative pain control.

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on propofol + ropivacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on propofol + ropivacaine.

Explore the full profile